Article Text

Download PDFPDF

Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas
  1. Marka Crittenden1,
  2. Keith S Bahjat2,
  3. Rui Li3,
  4. Pankaj Gore4,
  5. Chris Fountain3,
  6. Bill Hanson5,
  7. Justin Skoble5,
  8. Peter Lauer5,
  9. Aimee L Murphy5,
  10. Thomas Dubensky5,
  11. Dirk G Brockstedt5 and
  12. Walter Urba6
  1. Aff1 grid.420050.30000000404559389Earle A. Chiles Research Institute, Providence Cancer Center; The Oregon Clinic Portland OR USA
  2. Aff2 grid.415286.c0000 0004 0463 5556Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Center Portland OR USA
  3. Aff3 grid.415337.7Providence Cancer Center Portland OR USA
  4. Aff4 Microneurosurgical Consultants Portland OR USA
  5. Aff5 grid.417411.6Aduro Biotech Inc. Berkeley CA USA
  6. Aff6 grid.415286.c0000 0004 0463 5556Earle A. Chiles Research Institute Portland OR USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


The neo-antigen EGFRvIII is expressed in multiple tumor types, including high-grade astrocytomas. It is associated with a poor prognosis and resistance to conventional therapies such as chemotherapy and radiation that are part of the standard treatment. We propose that immunization with a live-attenuated Listeria-based vaccine, ADU-623, expressing EGFRvIII and NY-ESO-1 will elicit robust tumor-specific immune responses capable of killing EGFRvIII and/or NY-ESO-1-expressing tumor cells and improve survival of the patients. In addition, ADU-623 induces a potent innate immune response that can kill transformed cells even in the absence of neo-antigens. We designed a translational vaccine study to evaluate the safety and immunogenicity of this vaccine in patients with high-grade astrocytomas after standard of care therapy or at progression.


Patients with a pathologic diagnosis of WHO Grade III/IV astrocytic tumors that have completed standard of care external beam radiation therapy and concurrent temozolomide followed by adjuvant temozolomide or with radiographic evidence of progression following standard of care radiation and chemotherapy treatment, including those who have gone on to a second surgical resection are eligible. Patients are enrolled and assigned consecutively to one of the following ADU-623 dose level cohorts: Cohort 1 3x107 cfu, Cohort 2 3x108 cfu, or Cohort 3 1x109 cfu, each administered IV on Days 0, 21, 42 and 63. Adverse events are monitored throughout the treatment and patients are followed for up to 24 months. Patients are currently accruing to Cohort 3. The primary objective is to determine the maximum tolerated dose and characterize the safety profile of ADU-623 in patients with treated and recurrent WHO Grade III/IV astrocytomas. Secondary objectives include progression free survival, time to progression and overall survival rates in patients vaccinated with ADU-623. Exploratory studies of EGFRvIII-, NY-ESO-1-, vector-specific and innate immune responses will be performed.

Trial registration identifier NCT01967758.